

**Pediatric HIV/AIDS Cohort Study (PHACS)
Surveillance Monitoring of ART Toxicities (SMARTT) Study
Annual Administrative Report**

**Report Date: May 27, 2016
Data Retrieval Date: April 1, 2016**

**Created By:
Yanling Huo
Cenk Yildirim
Kathy Tassiopoulos
Paige Williams**

**Data Management by:
Angela Ellis**

Funding: The Pediatric HIV/AIDS Cohort Study (PHACS) network is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development with co-funding from other NIH institutes through cooperative agreements with the Harvard T.H. Chan School of Public Health [grant number HD052102] and the Tulane University School of Medicine [HD052104].

Use: This report is intended primarily for generating data analysis concept sheets and substudy proposals for PHACS. Information contained in the report also may be used in presentations and published manuscripts with acknowledgement or citation.

Suggested Citation for Publications: Pediatric HIV/AIDS Cohort Study (PHACS) SMARTT Annual Administrative Report, May 27, 2016. Boston, MA: PHACS Data and Operations Center. Accessed from <https://phacsstudy.org/>. Date accessed: [insert date].

Tables:

Table 1: SMARTT - Study Enrollment by Cohort and Quarter	6
Table 2: SMARTT - Study Enrollment by Site.....	7
Table 3: SMARTT - Enrollment by Previous Protocol Participation (Static cohort only)	8
Table 4: SMARTT - Enrollment Demographics	9
Table 5: SMARTT - Baseline Maternal Pregnancy and Delivery History Characteristics	10
Table 6: SMARTT - Study Status	11
Table 7: SMARTT - Age at Last Scheduled Clinic Visit Among Participants Still on Study.....	11
Table 8: SMARTT - Entry Visit Status	12
Table 9: Bayley Screen for Three Year-Olds	13
Table 10: Age-specific ND Assessments.....	14
Table 11: SMARTT Caregiver-Reported Hearing Information at Entry.....	15
Table 12: SMARTT Age-Specific Language Assessments	16
Table 13: SMARTT Growth Data at Entry.....	16
Table 14: Maternal Substance Use During Pregnancy in Dynamic SMARTT	17
Table 15: In Utero ARV Exposure by Birth Year, Static and Dynamic Cohorts Combined	19

Figures:

Figure 1: <i>In Utero</i> NRTI Exposures by Year of Birth	20
Figure 2: <i>In Utero</i> NNRTI Exposures by Year of Birth.....	20
Figure 3: <i>In Utero</i> PI Exposures by Year of Birth	21
Figure 4: <i>In Utero</i> F/II Exposures by Year of Birth.....	21
Figure 5: Five Most Common <i>in Utero</i> ARV Regimens by Year of Birth	22

Summary

As of April 1, 2016, 3867 children and 2982 caregivers enrolled in SMARTT ([Table 1](#)). As shown in the table, there were 2388 children in the dynamic cohort and 1240 in the static cohort (enrollment for the static cohort was closed on July 31, 2009). Starting in March 2010, a cohort of 200 HIV-unexposed, uninfected children was enrolled (50 each from four specific age groups [1, 3, 5, and 9 years old]) to serve as a reference group. After enrollment into the reference cohort began, echocardiograms were added to the schedule of evaluations for 3- and 5-year olds. In order to ensure a sufficient number of echocardiograms, 35 additional children from the 3- and 5-year old groups were enrolled into a modified reference cohort. A total of 239 children were enrolled in the reference cohort and evaluations are now complete. These children completed a limited set of evaluations including echocardiograms.

Enrollment by site is summarized in [Table 2](#). For the static cohort, most children (79%) previously participated in a PACTG/IMPAACT protocol: 24% in P1025 only; 23% in 219/219C; 13% in WITS only; 7% in 219/219C and WITS; 6% in 219C and P1025; 2% in 219C, P1025 and WITS ([Table 3](#)). Approximately half of the children enrolled were male ([Table 4](#)). Most children were Black or African American (65%), and of non-Hispanic ethnicity (69%). The median age at enrollment of children in the static cohort was 4.1 years. The numbers of children enrolled in the different age groups of the reference cohort are: 52 one-year olds; 67 three-year olds; 71 five-year olds and 49 nine-year olds.

As shown in [Table 5](#), 78% of infants were born at at least 37 weeks gestation and the majority weighed at least 2500 g (82%). The mode of delivery was known in 99% of children with some delivery information obtained, with 44% delivered by spontaneous vaginal delivery, 40% delivered by C-section before labor/membrane rupture and 13% delivered by C-section after labor/membrane rupture. [Note that the dynamic cohort allows study entry during gestation; thus birth characteristics may not yet be available]. Of the children enrolled in the dynamic and static cohorts, 85% and 74% children are still on study as of the last data retrieval date, respectively; 261 (11%) dynamic and 187 (15%) static children were withdrawn / lost to follow-up; and 56 (2%) dynamic and 52 (4%) static children were off study because of site closure ([Table 6](#)). A total of 28 children were off study because of death: 11 cases of intrauterine fetal demise, 4 of SIDS, 1 of complication from extensive burn, 1 of acute lymphoblastic leukemia, 1 of complication of Trisomy 21, 1 of motor vehicle accident, 1 of extreme prematurity, 1 of septic shock, 1 secondary to gunshot wound, 1 cardiac arrest and 5 undetermined. Nine dynamic children have gone off study due to HIV infection. Among children in the dynamic and static cohorts who were still on study, the median age at the last clinic visit for the dynamic and static cohorts were 3.8 and 11 years, respectively ([Table 7](#)). Overall, 97% of the children enrolled completed the entry visit and 89% of visits were done on time or early ([Table 8](#)). Three children missed the entry visit and 83 (2%) children dropped out of the study before the first study visit.

Tables 9 - 14 contain some initial summaries of key measures across domains of interest for SMARTT, including cognitive assessments (Tables 9 and 10), hearing and language assessments (Tables 11 and 12), growth data (Table 13), and maternal substance use during pregnancy (Table 14).

[Table 9](#) summarizes the results of the Bayley Screen for three-year olds. Of the subjects assessed, 32-55% of the dynamic cohort, 31-53% of the static cohort and 16-49% of the reference cohort were at risk (at risk/some risk) of developmental delay across the different sub-domains, with the highest percentage for cognitive delay and lowest percentage for gross motor delay. Overall, at least 41 subjects (dynamic: 30; static: 11) were identified to require further evaluation for delay in at least one of the assessed skills categories.

Neurodevelopment assessments for other ages are summarized in [Table 10](#), including the Full Bayley-III (1-year olds), WPPSI (5-year olds), WASI and WIAT for 7 years and older (performed at age-specific visits according to protocol), and BRIEF-SR for those 11 years and older (performed at age-specific visits according to protocol). The normative scores for the Bayley -III, WPPSI, WASI and WIAT have a mean of 100 and a standard deviation of 15. The normative scores for the BRIEF have a mean of 50 and a standard deviation of 10. As shown in the table, the mean scores across different neurodevelopment batteries were mostly within 5 – 10 points of the general population norms.

Information related to caregiver-reported hearing information is summarized in [Table 11](#), which indicates that overall, 26% of children (24% of dynamic cohort, 29% of static cohort and 21% of reference cohort) had an audiologic exam before enrolling in the study; 7 (all from the static cohort) of whom were identified with permanent hearing loss. Summary measures for the age-specific language assessments are provided in [Table 12](#), including the MacArthur CDI (1-year olds), Ages and Stages Questionnaire (ASQ: 2-year olds), TELD (3-year olds), and TOLD (5-year olds). The normative scores are 50th percentile for the CDI, and 100 (standard deviation: 15) for TELD and TOLD. The general population means are age specific for the ASQ. As shown in the table, the mean scores of MacArthur CDI, TELD and TOLD were mostly within 5 – 10 points of the general population; the means of ASQ were about 45.

The growth measurements in [Table 13](#) suggest that infants enrolled in the dynamic cohort were below average length and weight at birth, while those in the static cohort and reference cohort were above average height/length and weight for their ages at the time of study entry. The mean BMI (≥ 2 years old) for the static cohort and reference cohort were also higher than average.

[Table 14](#) summarizes self-reported substance use during pregnancy by mothers in the dynamic cohort, by trimester of pregnancy. Overall, 556 (30%) women reported some substance use (licit or illicit) at some point during their pregnancy. Substance use was highest during the first trimester and then decreased; cigarette smoking (19%) was the most frequently reported substance, followed by alcohol (10%) and marijuana (9%).

In utero ARV exposure by birth year for static and dynamic cohorts combined is summarized in [Table 15](#). Overall, of the 3464 children who completed a scheduled study visit, 3315 (96%) were exposed *in utero* to an ARV; 41 (1%) were exposed to ARV during labor and delivery only; while 36 (1%) were not exposed to any ARV during pregnancy, labor, or delivery.

[Figure 1 - Figure 4](#) show the trends of *in utero* ARV exposure by year of birth, for each ARV class and the individual agents within each class. Calculations are based on the number of children with *in utero* ARV exposure data available. Prenatal exposure to NRTI-containing regimens remained very high (nearly 100%) across all birth years ([Figure 1](#)). There was a decreasing trend in zidovudine (ZDV) exposure over time (from 100% in 1995 to about 27% in 2015); lamivudine (3TC) exposure increased dramatically from about 5% in 1996 to more than 90% in 2000 and fluctuated around this percentage till 2005, then decreased thereafter with a similar trend as ZDV; abacavir (ABC) became a common NRTI agent received during pregnancy after 2002, with use decreasing after 2007; tenofovir (TDF) and emtricitabine (FTC) use increased consistently from about 3% in 2002 to about 78% in 2015, and from about 1% in 2004 to about 76% in 2015, respectively; in addition, TDF and FTC surpassed ZDV and 3TC as the most commonly used NRTI agents in 2012. The use of NNRTI-containing regimens increased from about 5% in 1996 to more than 30% in 2003, then decreased to about 10% between 2008 and 2011 and then increased again to about 34% in 2015 ([Figure 2](#)). Nevirapine (NPV) was the most commonly used NNRTI agent, with use increasing between 1996 and 2003, and decreasing since then (less than 1% exposure in 2015); the use of efavirenz (EFV) was consistently low (less than 10%); there has been an increasing trend in the use of rilpivirine (RPV) since 2012 (increased from 4% in 2012 to about 30% in 2015). Starting in 1997, the use of PI-containing regimens increased to about 86% in 2010, and decreased since then ([Figure 3](#)). Nelfinavir (NFV) was initially the most commonly-used PI, but in 2007 it was surpassed by use of ritonavir boosted PIs, and that trend continues. Lopinavir exposure increased between 2001 and 2009 and has decreased since then. There was also an increasing trend in the use of atazanavir between 2004 and 2013; use has decreased since then. The first reported use of a Fusion Inhibitor (FI) was in 2006 and of an Integrase Inhibitor (II) was in 2008 ([Figure 4](#)); use of the FIs enfurvirtide (ENF) and maraviroc (MVC) have remained low; use of the II raltegravir (RAL) increased from about 1% in 2008 to about 16% in 2013, and then decreased to about 11% in 2015; use of elvitegravir (EVG) paired with cobicistat (a non-ARV booster for EVG), and in combination with FTC and TDF (as Stribild) emerged in 2013 and increased from 1% to about 12% in 2015; dolutegravir (DTG) use was first reported in 2014 at about 2% and increased to about 14% in 2015. The most commonly-used regimen has changed over time; ZDV monotherapy was the most commonly-used regimen before 1999, then ZDV+3TC in 1999, ZDV+3TC+NFV between 2000 and 2007, and ZDV+3TC+lopinavir/r after 2007 until 2014 when TDF+FTC+boosted ATV became the most frequently used regimen in 2014 and TDF+FTC+RPV in 2015 ([Figure 5](#)).

The median duration of follow-up in SMARTT was 93 months among Static and 47 months among Dynamic participants. The follow-up time is based on the assumption that a subject is still on study as of the last data retrieval date unless known to have discontinued. It is not based on their last study visit.

Tables and Figures

Table 1: SMARTT - Study Enrollment by Cohort and Quarter

Enrollment quarter	Cohort			
	Caregiver (N=2982)	Dynamic (N=2388)	Static (N=1240)	Reference (N=239)
2007 Q1	4 (0%)	0 (0%)	5 (0%)	0 (0%)
2007 Q2	167 (6%)	28 (1%)	185 (15%)	0 (0%)
2007 Q3	204 (7%)	51 (2%)	227 (18%)	0 (0%)
2007 Q4	145 (5%)	51 (2%)	127 (10%)	0 (0%)
2008 Q1	183 (6%)	79 (3%)	149 (12%)	0 (0%)
2008 Q2	142 (5%)	77 (3%)	95 (8%)	0 (0%)
2008 Q3	130 (4%)	79 (3%)	84 (7%)	0 (0%)
2008 Q4	126 (4%)	80 (3%)	106 (9%)	0 (0%)
2009 Q1	127 (4%)	89 (4%)	90 (7%)	0 (0%)
2009 Q2	128 (4%)	79 (3%)	109 (9%)	0 (0%)
2009 Q3	113 (4%)	81 (3%)	63 (5%)	0 (0%)
2009 Q4	65 (2%)	78 (3%)	0 (0%)	0 (0%)
2010 Q1	57 (2%)	61 (3%)	0 (0%)	2 (1%)
2010 Q2	73 (2%)	73 (3%)	0 (0%)	8 (3%)
2010 Q3	82 (3%)	72 (3%)	0 (0%)	30 (13%)
2010 Q4	82 (3%)	61 (3%)	0 (0%)	38 (16%)
2011 Q1	90 (3%)	74 (3%)	0 (0%)	41 (17%)
2011 Q2	67 (2%)	63 (3%)	0 (0%)	25 (10%)
2011 Q3	83 (3%)	61 (3%)	0 (0%)	52 (22%)
2011 Q4	58 (2%)	65 (3%)	0 (0%)	5 (2%)
2012 Q1	56 (2%)	57 (2%)	0 (0%)	10 (4%)
2012 Q2	66 (2%)	74 (3%)	0 (0%)	12 (5%)
2012 Q3	49 (2%)	56 (2%)	0 (0%)	7 (3%)
2012 Q4	43 (1%)	49 (2%)	0 (0%)	6 (3%)
2013 Q1	50 (2%)	64 (3%)	0 (0%)	3 (1%)
2013 Q2	58 (2%)	73 (3%)	0 (0%)	0 (0%)
2013 Q3	61 (2%)	75 (3%)	0 (0%)	0 (0%)
2013 Q4	53 (2%)	67 (3%)	0 (0%)	0 (0%)
2014 Q1	54 (2%)	65 (3%)	0 (0%)	0 (0%)
2014 Q2	47 (2%)	61 (3%)	0 (0%)	0 (0%)
2014 Q3	43 (1%)	58 (2%)	0 (0%)	0 (0%)
2014 Q4	43 (1%)	60 (3%)	0 (0%)	0 (0%)
2015 Q1	51 (2%)	64 (3%)	0 (0%)	0 (0%)
2015 Q2	46 (2%)	62 (3%)	0 (0%)	0 (0%)

	Cohort			
	Caregiver (N=2982)	Dynamic (N=2388)	Static (N=1240)	Reference (N=239)
2015 Q3	52 (2%)	68 (3%)	0 (0%)	0 (0%)
2015 Q4	44 (1%)	77 (3%)	0 (0%)	0 (0%)
2016 Q1	40 (1%)	56 (2%)	0 (0%)	0 (0%)

Reference cohort started enrolling in Q1 of 2010

Created by: /home/phacs/actgPH100/monitoring/programs/qad.sas

Table 2: SMARTT - Study Enrollment by Site

Enrollment site	Total (N=3867)	Dynamic (N=2388)	Cohort	
			Static (N=1240)	Reference (N=239)
NYU MEDICAL CTR/BELLEVUE	120 (3%)	62 (3%)	58 (5%)	0 (0%)
UNIVERSITY OF ALABAMA AT BIRMINGHAM *	167 (4%)	114 (5%)	29 (2%)	24 (10%)
UNIVERSITY OF SOUTHERN CALIFORNIA	325 (8%)	241 (10%)	84 (7%)	0 (0%)
SAN JUAN RESEARCH HOSPITAL	132 (3%)	71 (3%)	61 (5%)	0 (0%)
ST. JUDE CHILDREN'S RESEARCH HOSPITAL *	276 (7%)	208 (9%)	44 (4%)	24 (10%)
SUNY DOWNSTATE MEDICAL CENTER *	250 (6%)	109 (5%)	119 (10%)	22 (9%)
UNIV OF COLORADO HEALTH SCIENCES CENTER	190 (5%)	126 (5%)	64 (5%)	0 (0%)
NEW JERSEY MEDICAL CENTER	89 (2%)	81 (3%)	8 (1%)	0 (0%)
SUNY STONY BROOK MEDICAL CENTER	25 (1%)	8 (0%)	17 (1%)	0 (0%)
CHILDREN'S DIAG AND TREAT CTR (S FLOR) *	128 (3%)	80 (3%)	22 (2%)	26 (11%)
BRONX/LEBANON HOSPITAL CENTER *	420 (11%)	242 (10%)	137 (11%)	41 (17%)
UNIVERSITY OF FLORIDA HEALTH SCIENCE CTR	266 (7%)	168 (7%)	98 (8%)	0 (0%)
UNIVERSITY OF ILLINOIS (CHICAGO) *	208 (5%)	99 (4%)	88 (7%)	21 (9%)
UNIVERSITY OF PUERTO RICO MEDICAL CENTER	202 (5%)	112 (5%)	90 (7%)	0 (0%)
CHILDREN'S HOSPITAL OF PHILADELPHIA	27 (1%)	20 (1%)	7 (1%)	0 (0%)
UNIVERSITY OF MIAMI *	335 (9%)	256 (11%)	40 (3%)	39 (16%)
TEXAS CHILDREN'S HOSPITAL (BAYLOR) *	229 (6%)	123 (5%)	82 (7%)	24 (10%)
UNIVERSITY HEALTH SCIENCE CTR (TULANE) *	105 (3%)	76 (3%)	11 (1%)	18 (8%)
UCSD MEDICAL CENTER	106 (3%)	68 (3%)	38 (3%)	0 (0%)
UNIVERSITY OF MARYLAND MED CTR	42 (1%)	24 (1%)	18 (1%)	0 (0%)
JACOBI MEDICAL CENTER	35 (1%)	12 (1%)	23 (2%)	0 (0%)
CHILDREN'S MEMORIAL HOSPITAL OF CHICAGO	190 (5%)	88 (4%)	102 (8%)	0 (0%)

Sites with * enroll reference cohort

Created by: /home/phacs/actgPH100/monitoring/programs/qad.sas

Table 3: SMARTT - Enrollment by Previous Protocol Participation (Static cohort only)

Protocol group	Studies	Static (N=1240)	
No Previous Protocol	None	264 (21%)	
219/219C/P1025	P1025+NATURAL HISTORY	1 (0%)	
	P1025	293 (24%)	
	219C+P1025	75 (6%)	
	219/219C	291 (23%)	
	219	2 (0%)	
	Total	662 (53%)	
	WITS Only	WITS	159 (13%)
219/219C/P1025+WITS	P1025+WITS	5 (0%)	
	219C+P1025+WITS	20 (2%)	
	219/219C+WITS	90 (7%)	
	Total	115 (9%)	
Other PACTG/IMPAACT	PACTG 1039	3 (0%)	
	PACTG 1025	1 (0%)	
	PACTG 1022	1 (0%)	
	ACTG A5084	2 (0%)	
	ACTG 394	1 (0%)	
	ACTG 367	1 (0%)	
	ACTG 354	1 (0%)	
	ACTG 353	2 (0%)	
	ACTG 326	2 (0%)	
	ACTG 316/247	1 (0%)	
	ACTG 316	7 (1%)	
	ACTG 247	1 (0%)	
	Total	23 (2%)	
	Other	PACTG 386	1 (0%)
		NATURAL HISTORY	15 (1%)
CHS		1 (0%)	
Total		17 (1%)	

Created by: /home/phacs/actgPH100/monitoring/programs/qad.sas on April 1, 2016

Above table summarizes enrollment in previous studies based on the information provided at PHACS enrollment. 219/219C, P1025, and WITS enrollment information was captured for all static participants. However, enrollment information for other studies was only captured at PHACS enrollment for participants who did not participate in 219/219C, P1025, or WITS. Children in the dynamic cohort may also be enrolled in other studies (e.g. P1025).

Table 4: SMARTT - Enrollment Demographics

		Cohort			
		Total (N=3867)	Dynamic (N=2388)	Static (N=1240)	Reference (N=239)
Sex	Male	1951 (50%)	1189 (50%)	643 (52%)	119 (50%)
	Female	1845 (48%)	1128 (47%)	597 (48%)	120 (50%)
	Missing - Form not submitted	71 (2%)	71 (3%)	0 (0%)	0 (0%)
Age* at enrollment (yrs)	Median	4.1	.	4.1	4.7
	Birth	2417 (63%)	2388 (100%)	29 (2%)	0 (0%)
	1-2	404 (10%)	0 (0%)	352 (28%)	52 (22%)
	3-4	358 (9%)	0 (0%)	291 (23%)	67 (28%)
	5-6	277 (7%)	0 (0%)	206 (17%)	71 (30%)
	7-12	411 (11%)	0 (0%)	362 (29%)	49 (21%)
Race	Asian	20 (1%)	9 (0%)	7 (1%)	4 (2%)
	Native Hawaiian or other Pacific Islander	2 (0%)	1 (0%)	1 (0%)	0 (0%)
	Black or African American	2521 (65%)	1586 (66%)	765 (62%)	170 (71%)
	White	1001 (26%)	592 (25%)	350 (28%)	59 (25%)
	American Indian	7 (0%)	6 (0%)	1 (0%)	0 (0%)
	More than One Race	115 (3%)	92 (4%)	23 (2%)	0 (0%)
	Subject does not want to report	7 (0%)	2 (0%)	4 (0%)	1 (0%)
	Subject does not know	74 (2%)	38 (2%)	32 (3%)	4 (2%)
	Race not available to clinic	120 (3%)	62 (3%)	57 (5%)	1 (0%)
Ethnicity	Hispanic or Latino	1154 (30%)	676 (28%)	424 (34%)	54 (23%)
	Not Hispanic or Latino	2668 (69%)	1679 (70%)	806 (65%)	183 (77%)
	More than one ethnicity	39 (1%)	31 (1%)	8 (1%)	0 (0%)
	Subject does not want to report	1 (0%)	0 (0%)	1 (0%)	0 (0%)
	Subject does not know	4 (0%)	2 (0%)	1 (0%)	1 (0%)
	Ethnicity not available to clinic	1 (0%)	0 (0%)	0 (0%)	1 (0%)

*Age is rounded to the nearest year. So a child who enrolled at 4 years 11 months is in the 5-6 year group.

Age at enrollment for reference cohort is 1, 3, 5 or 9 years old

Created by: /home/phacs/actgPH100/monitoring/programs/qad.sas

Table 5: SMARTT - Baseline Maternal Pregnancy and Delivery History Characteristics

Characteristic		Cohort			
		Total (N=3691)	Dynamic (N=2285)	Static (N=1178)	Reference (N=228)
Gestational Age at Birth*	<32	87 (2%)	51 (2%)	31 (3%)	5 (2%)
	32-<37	608 (16%)	378 (17%)	205 (17%)	25 (11%)
	37+	2,885 (78%)	1,845 (81%)	860 (73%)	180 (79%)
	Unknown	111 (3%)	11 (0%)	82 (7%)	18 (8%)
Weight at Birth	<2500 g	653 (18%)	397 (17%)	219 (19%)	37 (16%)
	>=2500 g	3,037 (82%)	1,887 (83%)	959 (81%)	191 (84%)
	Unknown	1 (0%)	1 (0%)	0 (0%)	0 (0%)
Mode of Delivery	Spontaneous Vaginal	1,633 (44%)	929 (41%)	556 (47%)	148 (65%)
	Assisted Vaginal (Forceps, Vacuum)	70 (2%)	30 (1%)	25 (2%)	15 (7%)
	C-Section Before Labor/Membrane Rupture	1,479 (40%)	993 (43%)	449 (38%)	37 (16%)
	C-Section After Labor/Membrane Rupture	488 (13%)	328 (14%)	132 (11%)	28 (12%)
	Unknown Delivery Mode	21 (1%)	5 (0%)	16 (1%)	0 (0%)
Apgar Score at One Minute	< 7	312 (8%)	220 (10%)	92 (8%)	0 (0%)
	>=7	2,988 (81%)	2,033 (89%)	955 (81%)	0 (0%)
	Unknown	391 (11%)	32 (1%)	131 (11%)	228 (100%)
Apgar Score at Minute Five	< 7	61 (2%)	44 (2%)	17 (1%)	0 (0%)
	>=7	3,242 (88%)	2,211 (97%)	1,031 (88%)	0 (0%)
	Unknown	388 (11%)	30 (1%)	130 (11%)	228 (100%)

Above calculations are based on 3867 children enrolled in the study: 1240 in the static cohort, 2388 in the dynamic cohort and 239 in the reference cohort. In the static cohort, 41 children did not have forms submitted at this time and 21 did not have their submitted forms completed. In the dynamic cohort, 83 children did not have forms submitted at this time and 20 did not have their submitted forms completed. In the reference cohort, 3 children did not have forms submitted at this time and 8 did not have their submitted forms completed.

* Gestational age is first based on obstetrical gestational age data and when not available, then pediatric gestational age.

Created by: /home/phacs/actgPH100/monitoring/detlprogs/infantbl.sas

Table 6: SMARTT - Study Status

		Cohort			
		Total (N=3867)	Dynamic (N=2388)	Static (N=1240)	Reference (N=239)
Study status	Still on study	2951 (76%)	2029 (85%)	922 (74%)	0 (0%)
	Completed study	304 (8%)	0 (0%)	73 (6%)	231 (97%)
	Enrollment error / eligibility failure*	11 (0%)	9 (0%)	2 (0%)	0 (0%)
	Death of subject	28 (1%)	26 (1%)	2 (0%)	0 (0%)
	Withdrawal / loss to follow-up	455 (12%)	261 (11%)	187 (15%)	7 (3%)
	Site closure	108 (3%)	56 (2%)	52 (4%)	0 (0%)
	Other reason	10 (0%)	7 (0%)	2 (0%)	1 (0%)

* 9 children in the Enrollment error/eligibility failure category are HIV-infected

Created by: /home/phacs/actgPH100/monitoring/programs/qad.sas

Table 7: SMARTT - Age at Last Scheduled Clinic Visit Among Participants Still on Study

Characteristic		Cohort		
		Total (N=2951)	Dynamic (N=2029)	Static (N=922)
Age at Last Scheduled Clinical Visit	Median (Min, Max)	5.1 (0.0, 17.3)	3.8 (0.0, 8.3)	11.0 (6.0, 17.3)
	0	317 (11%)	317 (16%)	0 (0%)
	1-2	476 (16%)	476 (23%)	0 (0%)
	3-4	459 (16%)	459 (23%)	0 (0%)
	5-6	478 (16%)	477 (24%)	1 (0%)
	7-12	994 (34%)	300 (15%)	694 (75%)
	13-15	224 (8%)	0 (0%)	224 (24%)
	>15	3 (0%)	0 (0%)	3 (0%)

* For participants who did not attend the scheduled study visits, the scheduled clinical visit date was used to calculate the age.

Created by: /home/phacs/actgPH100/monitoring/detlprogs/currage.sas

Table 8: SMARTT - Entry Visit Status

Visit status	Total	Cohort		
		Dynamic	Static	Reference
Visit reported	3751 (97%)	2315 (97%)	1200 (97%)	236 (99%)
Early	26 (1%)	1 (0%)	21 (2%)	4 (2%)
In window	3395 (88%)	2193 (92%)	999 (81%)	203 (85%)
Late	330 (9%)	121 (5%)	180 (15%)	29 (12%)
No visit reported	116 (3%)	73 (3%)	40 (3%)	3 (1%)
In window	30 (1%)	30 (1%)	0 (0%)	0 (0%)
Missed visit	3 (0%)	3 (0%)	0 (0%)	0 (0%)
Off study	83 (2%)	40 (2%)	40 (3%)	3 (1%)

Table (above) reports on the status and timeliness of the entry visit for all enrolled subjects. This is based on the Visit Report form (PH5801) and the subject's birthday. For the static cohort and reference cohort, the allowed visit window is the birthday +/- 90 days.

For the dynamic cohort, the permitted visit window is from after birth up to two weeks. A visit is Delinquent if no visit has been reported, the visit window has passed, and an additional 2 weeks have passed (to allow time for submission of PH5801). This is a total of 4 weeks from an infant's birthdate. For those infants with no recorded birthdate, an estimated delivery date has been generated based on 43 weeks of gestation (or the visit date on PH5801).

Table 9: Bayley Screen for Three Year-Olds

ND Assessment		Cohort			
		Total (N=1084)	Dynamic (N=766)	Static (N=275)	Reference (N=43)
Cognitive	At Risk for Devl Delay/Further Eval Needed	41 (3.8%)	30 (3.9%)	11 (4.0%)	0 (0.0%)
	Some Risk for Devl Delay	548 (50.6%)	392 (51.2%)	135 (49.1%)	21 (48.8%)
	Low Risk for Devl Delay	495 (45.7%)	344 (44.9%)	129 (46.9%)	22 (51.2%)
Receptive Communication	At Risk for Devl Delay/Further Eval Needed	26 (2.4%)	15 (2.0%)	11 (4.0%)	0 (0.0%)
	Some Risk for Devl Delay	403 (37.2%)	292 (38.1%)	97 (35.3%)	14 (32.6%)
	Low Risk for Devl Delay	653 (60.2%)	457 (59.7%)	167 (60.7%)	29 (67.4%)
	Not Done	2 (0.2%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
Expressive Communication	At Risk for Devl Delay/Further Eval Needed	38 (3.5%)	29 (3.8%)	9 (3.3%)	0 (0.0%)
	Some Risk for Devl Delay	427 (39.4%)	309 (40.3%)	108 (39.3%)	10 (23.3%)
	Low Risk for Devl Delay	617 (56.9%)	426 (55.6%)	158 (57.5%)	33 (76.7%)
	Not Done	2 (0.2%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
Fine Motor	At Risk for Devl Delay/Further Eval Needed	25 (2.3%)	17 (2.2%)	8 (2.9%)	0 (0.0%)
	Some Risk for Devl Delay	400 (36.9%)	297 (38.8%)	91 (33.1%)	12 (27.9%)
	Low Risk for Devl Delay	657 (60.6%)	450 (58.7%)	176 (64.0%)	31 (72.1%)
	Not Done	2 (0.2%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
Gross Motor	At Risk for Devl Delay/Further Eval Needed	21 (1.9%)	15 (2.0%)	6 (2.2%)	0 (0.0%)
	Some Risk for Devl Delay	316 (29.2%)	231 (30.2%)	78 (28.4%)	7 (16.3%)
	Low Risk for Devl Delay	744 (68.6%)	517 (67.5%)	191 (69.5%)	36 (83.7%)
	Not Done	3 (0.3%)	3 (0.4%)	0 (0.0%)	0 (0.0%)

Created by: /home/phacs/actgPH100/monitoring/detlprogs/NDassess.sas

Table 10: Age-specific ND Assessments

ND Assessment	Score	Cohort					
		Dynamic		Static		Reference	
		N	Mean (S.D)	N	Mean (S.D)	N	Mean (S.D)
Bayley-III (1 year old)	Cognitive, Composite	1180	103.2 (14.0)	146	102.9 (15.2)	49	102.2 (14.0)
	Language, Composite	1178	94.2 (13.6)	145	93.2 (14.7)	49	95.1 (12.5)
	Motor, Composite	1174	97.2 (12.4)	145	96.9 (15.9)	49	100.9 (14.7)
	Social-Emotional, Composite	1145	101.7 (17.4)	142	101.6 (18.5)	49	100.5 (16.4)
	General Adaptive, Composite	1143	94.9 (14.3)	142	93.4 (15.0)	49	92.3 (11.3)
WPPSI (5 years old)	Full Scale IQ	471	93.9 (15.0)	445	94.6 (14.5)	47	93.6 (15.6)
	Performance IQ	480	95.9 (15.1)	447	97.3 (15.2)	47	95.6 (15.3)
	Verbal IQ	478	92.1 (14.5)	447	92.1 (12.9)	47	91.6 (13.9)
	Processing Speed IQ	462	95.8 (15.6)	442	96.3 (15.9)	47	95.0 (15.4)
	General Language IQ	289	92.7 (13.9)	210	91.0 (14.1)	19	91.1 (11.4)
WASI (7+ odd years old)*	Full Scale IQ	0		708	97.7 (13.8)	48	100.8 (12.6)
	Performance IQ	0		708	95.0 (12.9)	49	95.3 (13.0)
	Verbal IQ	0		708	100.8 (15.8)	48	105.8 (14.2)
WIAT (7+ odd years old)*	Word Reading, Standard Score	0		706	97.3 (16.1)	49	97.1 (15.0)
	Spelling, Standard Score	0		703	98.0 (16.5)	48	98.8 (15.8)
	Numerical Operations, Standard Score	0		706	93.9 (16.5)	49	94.5 (15.5)
BRIEF (11+ odd years old)*	Inhibit, T-Score	0		135	48.5 (9.7)	0	
	Shift, T-Score	0		135	52.6 (12.2)	0	
	Emotional Control, T-Score	0		135	50.6 (10.1)	0	
	Monitor, T-Score	0		134	48.8 (10.5)	0	
	Behavioral Regulation Index, T-Score	0		134	50.2 (11.3)	0	
	Working Memory, T-Score	0		135	50.7 (11.2)	0	
	Plan/Organize, T-Score	0		135	47.1 (10.2)	0	
	Organization of Materials, T-Score	0		135	48.3 (9.8)	0	
	Task Completion, T-Score	0		133	49.4 (10.0)	0	
	Metacognition Index, T-Score	0		134	48.7 (10.8)	0	
	Global Executive Composite, T-Score	0		134	49.5 (11.2)	0	
	Behavioral Shift, T-Score	0		133	51.6 (11.8)	0	
	Cognitive Shift, T-Score	0		133	52.4 (11.2)	0	

* WASI, WIAT AND BRIEF: For subjects completing an assessment at more than one time point, the earliest assessment is used.

Created by: /home/phacs/actgPH100/monitoring/detlprogs/NDassess.sas

Table 11: SMARTT Caregiver-Reported Hearing Information at Entry

Characteristic		Cohort			
		Total (N=3738)	Dynamic (N=2307)	Static (N=1195)	Reference (N=236)
Concerns about hearing?	Yes	119 (3%)	33 (1%)	77 (6%)	9 (4%)
	No	3,576 (96%)	2,239 (97%)	1,111 (93%)	226 (96%)
	Unknown	43 (1%)	35 (2%)	7 (1%)	1 (0%)
Child has repeated ear infections?	Yes	124 (3%)	0 (0%)	102 (9%)	22 (9%)
	No	3,571 (96%)	2,272 (98%)	1,086 (91%)	213 (90%)
	Unknown	43 (1%)	35 (2%)	7 (1%)	1 (0%)
Child failed hearing screening?	Yes	140 (4%)	64 (3%)	65 (5%)	11 (5%)
	No	3,555 (95%)	2,208 (96%)	1,123 (94%)	224 (95%)
	Unknown	43 (1%)	35 (2%)	7 (1%)	1 (0%)
Child tested by audiologist?	Yes	961 (26%)	562 (24%)	349 (29%)	50 (21%)
	No	2,734 (73%)	1,710 (74%)	839 (70%)	185 (78%)
	Unknown	43 (1%)	35 (2%)	7 (1%)	1 (0%)
Perm hearing loss in 1-2 ears?	Yes	7 (0%)	0 (0%)	7 (1%)	0 (0%)
	No	952 (25%)	560 (24%)	342 (29%)	50 (21%)
	Not Required	2,735 (73%)	1,711 (74%)	839 (70%)	185 (78%)
	Unknown	44 (1%)	36 (2%)	7 (1%)	1 (0%)

Created by: /home/phacs/actgPH100/monitoring/det/progs/hearlang.sas

Table 12: SMARTT Age-Specific Language Assessments

	Dynamic		Static		Reference	
	Total N	Mean (S.D.)/ N (%)	Total N	Mean (S.D.)/ N (%)	Total N	Mean (S.D.)/ N (%)
MacArthur Phrases Understood	1313	56.6(26.8)	169	50.4(27.8)	47	52.6(27.8)
MacArthur Vocabulary Comprehension	1313	46.5(29.7)	169	43.8(29.6)	47	44.7(31.1)
MacArthur Words Production	1313	49(21.2)	169	45.1(21)	47	56.3(20)
MacArthur A-E Total Gestures	1313	50.7(27.9)	169	40.5(28.8)	47	55.9(30.9)
Ages and Stages Total Score	1223	44.3(15.4)	268	45(15.7)		(.)
TELD Receptive Language	37	98.9(16)	285	98.8(14.4)	37	97.8(11.1)
TELD Expressive Language	37	98.9(13.3)	285	99.6(14.7)	37	102.6(10.9)
TELD Spoken Language Quotient	37	95.6(22.6)	285	99.5(17.4)	37	98.1(19.8)
TOLD Spoken Language	436	91.2(14.2)	422	90.1(14.1)	45	87.9(14.3)
TOLD Listening	441	96.9(13.9)	423	94.6(13.6)	45	92(13.4)
TOLD Speaking	439	91.2(15)	423	91.6(14)	45	90.2(13.6)
TOLD Syntax	438	89.1(14.5)	423	89.4(14.5)	45	89(13.7)

Created by: /home/phacs/actgPH100/monitoring/detlprogs/heartlang.sas

Table 13: SMARTT Growth Data at Entry

Score	Dynamic			Static			Reference		
	N	Mean	S.D.	N	Mean	S.D.	N	Mean	S.D.
Height or Length Z-score	2286	-0.15	1.05	1191	0.31	1.13	234	0.33	1.14
Weight Z-score	2288	-0.59	0.86	1193	0.51	1.25	234	0.21	1.21
BMI Z-score (>= 2 yrs old)	.	.	.	844	0.63	1.30	171	0.15	1.26

BMI is not calculated for children < 2 years.

Z-scores for premature subjects are adjusted for newborn and 1-year olds.

Extreme growth Z-scores (> 6 in absolute values) were excluded from calculations and will be queried.

Created by: /home/phacs/actgPH100/monitoring/detlprogs/growthnut.sas

Table 14: Maternal Substance Use During Pregnancy in Dynamic SMARTT

		Trimester			
		Any Trimester (N=1865)	First (N=1865)	Second (N=1865)	Third (N=1865)
Any Substance Use	Yes	556 (30%)	486 (26%)	312 (17%)	293 (16%)
	No	1,307 (70%)	1,377 (74%)	1,551 (83%)	1,570 (84%)
	Missing	2 (0%)	2 (0%)	2 (0%)	2 (0%)
Tobacco	Yes	348 (19%)	327 (18%)	216 (12%)	190 (10%)
	No	1,515 (81%)	1,528 (82%)	1,639 (88%)	1,665 (89%)
	Missing	2 (0%)	10 (1%)	10 (1%)	10 (1%)
Alcohol	Yes	187 (10%)	169 (9%)	50 (3%)	41 (2%)
	No	1,676 (90%)	1,692 (91%)	1,811 (97%)	1,820 (98%)
	Missing	2 (0%)	4 (0%)	4 (0%)	4 (0%)
Marijuana	Yes	166 (9%)	149 (8%)	72 (4%)	57 (3%)
	No	1,697 (91%)	1,711 (92%)	1,788 (96%)	1,803 (97%)
	Missing	2 (0%)	5 (0%)	5 (0%)	5 (0%)
Cocaine	Yes	47 (3%)	37 (2%)	24 (1%)	18 (1%)
	No	1,816 (97%)	1,826 (98%)	1,839 (99%)	1,845 (99%)
	Missing	2 (0%)	2 (0%)	2 (0%)	2 (0%)
Antidepressants	Yes	74 (4%)	49 (3%)	33 (2%)	37 (2%)
	No	1,787 (96%)	1,812 (97%)	1,828 (98%)	1,824 (98%)
	Missing	4 (0%)	4 (0%)	4 (0%)	4 (0%)
Pain Medications	Yes	81 (4%)	40 (2%)	41 (2%)	36 (2%)
	No	1,781 (95%)	1,821 (98%)	1,820 (98%)	1,825 (98%)
	Missing	3 (0%)	4 (0%)	4 (0%)	4 (0%)
Methadone	Yes	10 (1%)	10 (1%)	10 (1%)	10 (1%)
	No	1,851 (99%)	1,852 (99%)	1,852 (99%)	1,852 (99%)
	Missing	4 (0%)	3 (0%)	3 (0%)	3 (0%)
Heroin	Yes	9 (0%)	7 (0%)	3 (0%)	2 (0%)
	No	1,854 (99%)	1,855 (99%)	1,859 (100%)	1,860 (100%)
	Missing	2 (0%)	3 (0%)	3 (0%)	3 (0%)
Sedative	Yes	10 (1%)	8 (0%)	5 (0%)	4 (0%)
	No	1,852 (99%)	1,854 (99%)	1,857 (100%)	1,858 (100%)
	Missing	3 (0%)	3 (0%)	3 (0%)	3 (0%)
Methamphetamines	Yes	9 (0%)	9 (0%)	4 (0%)	0 (0%)
	No	1,854 (99%)	1,854 (99%)	1,859 (100%)	1,863 (100%)
	Missing	2 (0%)	2 (0%)	2 (0%)	2 (0%)
Ecstasy	Yes	3 (0%)	3 (0%)	0 (0%)	0 (0%)
	No	1,860 (100%)	1,860 (100%)	1,863 (100%)	1,863 (100%)
	Missing	2 (0%)	2 (0%)	2 (0%)	2 (0%)
PCP	Yes	1 (0%)	1 (0%)	1 (0%)	1 (0%)
	No	1,861 (100%)	1,861 (100%)	1,861 (100%)	1,861 (100%)

		Trimester			
		Any Trimester (N=1865)	First (N=1865)	Second (N=1865)	Third (N=1865)
Opium	Missing	3 (0%)	3 (0%)	3 (0%)	3 (0%)
	Yes	2 (0%)	1 (0%)	1 (0%)	1 (0%)
	No	1,861 (100%)	1,862 (100%)	1,862 (100%)	1,862 (100%)
Other Drug	Missing	2 (0%)	2 (0%)	2 (0%)	2 (0%)
	Yes	11 (1%)	10 (1%)	7 (0%)	4 (0%)
	No	1,852 (99%)	1,853 (99%)	1,856 (100%)	1,859 (100%)
	Missing	2 (0%)	2 (0%)	2 (0%)	2 (0%)

No reported use of stimulants, amphetamines, inhalants, ketamine, LSD or other hallucinogens.

Created by: /home/phacs/actgPH100/monitoring/det/progs/matdrug.sas


Table 15: In Utero ARV Exposure by Birth Year, Static and Dynamic Cohorts Combined

Year of birth	During pregnancy	Labor and delivery only	No ARV during pregnancy labor and delivery	Unknown ARV use	Total
1995	6 (100%)	0 (0%)	0 (0%)	0 (0%)	6 (0%)
1996	33 (89%)	2 (5%)	2 (5%)	0 (0%)	37 (1%)
1997	27 (90%)	1 (3%)	2 (7%)	0 (0%)	30 (1%)
1998	48 (92%)	2 (4%)	0 (0%)	2 (4%)	52 (2%)
1999	66 (93%)	2 (3%)	2 (3%)	1 (1%)	71 (2%)
2000	87 (94%)	1 (1%)	3 (3%)	2 (2%)	93 (3%)
2001	91 (89%)	5 (5%)	4 (4%)	2 (2%)	102 (3%)
2002	98 (94%)	0 (0%)	2 (2%)	4 (4%)	104 (3%)
2003	117 (95%)	0 (0%)	2 (2%)	4 (3%)	123 (4%)
2004	108 (93%)	4 (3%)	3 (3%)	1 (1%)	116 (3%)
2005	124 (98%)	0 (0%)	2 (2%)	1 (1%)	127 (4%)
2006	149 (93%)	3 (2%)	3 (2%)	6 (4%)	161 (5%)
2007	226 (96%)	6 (3%)	1 (0%)	3 (1%)	236 (7%)
2008	339 (96%)	8 (2%)	2 (1%)	5 (1%)	354 (10%)
2009	316 (98%)	1 (0%)	2 (1%)	3 (1%)	322 (9%)
2010	258 (98%)	2 (1%)	0 (0%)	4 (2%)	264 (8%)
2011	260 (99%)	1 (0%)	0 (0%)	1 (0%)	262 (8%)
2012	230 (98%)	1 (0%)	1 (0%)	3 (1%)	235 (7%)
2013	251 (95%)	0 (0%)	2 (1%)	10 (4%)	263 (8%)
2014	236 (93%)	1 (0%)	3 (1%)	15 (6%)	255 (7%)
2015	243 (98%)	1 (0%)	0 (0%)	5 (2%)	249 (7%)
2016	2 (100%)	0 (0%)	0 (0%)	0 (0%)	2 (0%)
Total	3315 (96%)	41 (1%)	36 (1%)	72 (2%)	3464 (100%)

Includes births three months prior to current data download


Created by: /home/phacs/actgPH100/monitoring/detlprogs/mat_arv.sas

Figure 1: *In Utero* NRTI Exposures by Year of Birth




Number above the x-axis represents the number of children with in utero ARV exposure data available

Figure 2: *In Utero* NNRTI Exposures by Year of Birth




Number above the x-axis represents the number of children with in utero ARV exposure data available

Figure 3: *In Utero* PI Exposures by Year of Birth



Number above the x-axis represents the number of children with in utero ARV exposure data available

Figure 4: *In Utero* FI/II Exposures by Year of Birth



Number above the x-axis represents the number of children with in utero ARV exposure data available

